This white paper provides a summary of presentations, discussions and conclusions of a Thinktank entitled “The Role of Endpoint Adjudication in Medical Device Clinical Trials”. The think tank was cosponsored by the Cardiac Safety Research Committee, MDEpiNet and the US Food and Drug Administration (FDA) and was convened at the FDA's White Oak headquarters on March 11, 2016. Attention was focused on tailoring best practices for evaluation of endpoints in medical device clinical trials, practical issues in endpoint adjudication of therapeutic, diagnostic, biomarker and drug-device combinations, and the role of adjudication in regulatory and reimbursement issues throughout the device lifecycle. Attendees included representatives from medical device companies, the FDA, Centers for Medicare and Medicaid Services (CMS), end point adjudication specialist groups, clinical research organizations, and active, academically based adjudicators. The manuscript presents recommendations from the think tank regarding (1) rationale for when adjudication is appropriate, (2) best practices establishment and operation of a medical device adjudication committee and (3) the role of endpoint adjudication for post market evaluation in the emerging era of real world evidence. (Am Heart J 2017;190:76-85.)
In this issue of the journal, Jonathan Seltzer presents an important review of the rationale and best pract...
Request a Genetics in Clinical Trials training sessionWhat You'll Learn
Most Recent Flipbooks
16 industry experts share shifts and trends that will inform clinical research in 2020 and beyond.
From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations.
Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk